small molecule

PYRUKYND

MITAPIVAT SULFATE

Loss of exclusivityJuly 2041latest FDA-listed patent expiry

CompanyAgios Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	PYRUKYND
Active ingredient	MITAPIVAT SULFATE
Strength	EQ 5MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	February 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
11878049	July 2041	use U-3782
11254652	November 2038	substance, product
11234976	October 2038	use U-3321
RE49582	April 2035	substance, product
11793806	April 2033	use U-3320
9193701	October 2032	use U-3319
10632114	May 2032	use U-3320
9682080	May 2032	use U-3319
9980961	May 2032	use U-3319

Regulatory exclusivity

Code	Expires
ODE-392	February 2029
NCE	February 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Agios Pharmaceuticals